Exozymes grants Marlett options for 10,000 shares

Q: How many EXOZ options did Christopher A. Marlett receive, and at what exercise price?

Christopher A. Marlett received options to buy 10,000 shares at a $6.28 exercise price on October 1, 2026; the options expire October 1, 2033.

Q: What is the vesting schedule for Christopher A. Marlett's EXOZ options?

The award vests in 12 quarterly installments: 11 installments of 833 shares and a final installment of 837 shares, beginning December 31, 2026, and ending September 30, 2029, subject to his continued service with the issuer.

The option award is subject to continued service and vests quarterly through September 30, 2029.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Christopher A. Marlett, a director and 10% owner of EXOZ, received a direct award of options to buy 10,000 shares on October 1, 2026, with a $6.28 exercise price and an October 1, 2033 expiration. The options vest quarterly from December 31, 2026, through September 30, 2029, subject to his continued service with the issuer. Separately, MDB Capital Holdings, LLC held 3,808,476 common shares as of October 1, 2026. Marlett has voting and dispositive authority over those shares and disclaims any interest except to the extent of his pecuniary interests in the LLC.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 2 txns

Insider MARLETT CHRISTOPHER A

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) ^F1	10,000	$0.00	$0.00
holding	Common Stock ^F2	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct); Common Stock — 3,808,476 shares (Indirect, See Footnote)

Footnotes (2)

F1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 833 shares and a final installment of 837 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.
F2. Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC.

Key Figures

Options awarded: 10,000 shares Exercise price: $6.28 per share Vesting installments: 12 quarterly installments +4 more

7 metrics

Options awarded 10,000 shares Direct award on October 1, 2026

Exercise price $6.28 per share Options awarded October 1, 2026

Vesting installments 12 quarterly installments Beginning December 31, 2026; ending September 30, 2029

Shares per regular installment 833 shares 11 quarterly installments

Shares in final installment 837 shares Final quarterly installment

Option expiration October 1, 2033 Options awarded October 1, 2026

Common shares held by MDB Capital Holdings, LLC 3,808,476 shares As of October 1, 2026

Key Terms

Stock Option (right to buy), quarterly installments, voting and dispositive authority, pecuniary interests

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

quarterly installments technical

"twelve (12) quarterly installments"

voting and dispositive authority regulatory

"voting and dispositive authority"

pecuniary interests financial

"pecuniary interests in MDB Capital Holdings, LLC"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EXOZ options did Christopher A. Marlett receive, and at what exercise price?

Christopher A. Marlett received options to buy 10,000 shares at a $6.28 exercise price on October 1, 2026; the options expire October 1, 2033.

What is the vesting schedule for Christopher A. Marlett's EXOZ options?

The award vests in 12 quarterly installments: 11 installments of 833 shares and a final installment of 837 shares, beginning December 31, 2026, and ending September 30, 2029, subject to his continued service with the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 07:48 PM EDT Accepted by SEC EDGAR 10/19/2026 - 07:48 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARLETT CHRISTOPHER A

(Last)

(First)

(Middle)

C/O 14133 MIDWAY ROAD, SUITE G-150

(Street)

ADDISON

TEXAS

75001

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								3,808,476	I	See Footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.28	10/01/2026		A		10,000		⁽¹⁾	10/01/2033	Common Stock	10,000	$0.00	10,000	D

Explanation of Responses:

1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 833 shares and a final installment of 837 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.

2. Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC.

	/s/ Christopher Marlett	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR